If palpitations concern you, raise it before your next dose increase
The landmark SELECT trial significantly expanded the therapeutic paradigm by demonstrating a 20% relative risk reduction in three-point major adverse cardiovascular events (MACEs) with semaglutide 2.4 mg in 17,604 patients with obesity but without diabetes, leading to FDA approval for cardiovascular risk reduction in March 2024 [82]
Using clean injection sites, rotating locations, and following appropriate reconstitution procedures minimizes infection risk and local tissue reactions
We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea
Identify accountability partner, join support group, or establish regular check-ins with healthcare provider Environmental modification
Another study found that dogs fed 180 mg/kg SalB orally had an AUC of 1680 670 ng/mL h and a bioavailability of only 1.07% 0.43% (Gao et al., 2009)